Toxicity, uptae kinetics and efficacy of new transfetion reagents: Increase of oligonucleotide uptake

Journal of Vascular Research

Volumn 37, Issue 4, 2000, Pages 221-234

  Axel, Dorothea I ^a,c   Spyridopoulos, Ioakim ^a   Riessen, Reimer ^a   Runge, Heike ^a   Viebahn, Richard ^b   Karsch, Karl R ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Department of Surgery ^*  (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antisense oligonucleotides; Endothelial cells; Growth factors; Liposome; Restenosis; Smooth muscle cells; Transfection

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOFECTIN; OLIGONUCLEOTIDE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FLUORESCEIN ISOTHIOCYANATE; GROWTH PROMOTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; TRANSFORMING GROWTH FACTOR BETA;

CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESSENGER RNA SYNTHESIS; NORTHERN BLOTTING; PRIORITY JOURNAL; REVIEW; TOXICITY; VASCULAR DISEASE; WESTERN BLOTTING; ARTICLE; BIOSYNTHESIS; BLOOD VESSEL; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; GENETICS; METABOLISM; METHODOLOGY; MICROCAPSULE;

BLOOD VESSELS; CAPSULES; CELL SURVIVAL; CELLS, CULTURED; FLUORESCEIN-5-ISOTHIOCYANATE; GROWTH SUBSTANCES; HUMANS; INDICATORS AND REAGENTS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-SIS; RNA, MESSENGER; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033803008     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025737     Document Type: Review

References (57)

1. Nabel EG: Gene therapy for vascular diseases. Atherosclerosis 1995;118:S51-S56.
2. Robinson-Benion C, Holt JT: Antisense techniques. Methods Enzymol 1995;254:363-375.
3. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, Wild DH, Brehm BR, Riessen R, Köveker G, Karsch KR: Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645.
4. Asahara T, Takeshita S, Tsurumi Y, Feldman L, Isner JM: Arterial gene therapy: A molecular biological perspective for the treatment of arterial ischemia. Z Kardiol 1997;86(suppl 1): 65-69.
5. Feldman LJ, Steg G: Optimal techniques for arterial gene transfer. Cardiovasc Res 1997;35: 391-404.
6. Agrawal S, Iyer RP: Perspectives in antisense therapeutics. Pharmacol Ther 1997;76:151-160.
7. Alahari SK, DeLong R, Fisher MH, Dean NM, Viliet P, Juliano RL: Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther 1998;286:419-428.
8. Zhu NL, Wu LT, Liu PX, Gordon EM, Anderson WF, Starnes VA, Hall FL: Down-regulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 1997:96: 628-635.
9. Wheeler CJ, Sukhu L, Yang G, Tsai Y, Bustamente C, Felgner P, Norman J, Manthorpe M: Converting an alcohol to amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes. Biochim Biophys Acta 1996:1280:1-11.
10. Flugelman MY, Jaklitsch MT, Newman KD, Casscells W, Bratthauer GI, Diehek DA: Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation 1992;85:1110-1117.
11. Feldmann LJ, Steg PG, Zheng LP, Chen D, Kearney M, McGarr SE, Barry JJ, Dedieu JF, Perricaudet M, Isner JM: Low efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest 1997;95:2662-2671.
12. Fife K, Bower M, Cooper RG, Stewart L, Etheridge CJ, Coombes RC, Buluwela L, Miller AD: Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing. Gene Ther 1998;5:614-620.
13. Yang Y, Nunes FA, Berenesi K, Furth EE, Gonezol E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994:91:4407-4411.
14. Feldman LJ, Tahlil O, Steg G: Perspectives of arterial gene therapy for the prevention of restenosis. Cardiovasc Res 1996;32:194-207.
15. Pickering JG, Takeshita S, Feldman J, Losordo DW, Isner JM: Vascular applications of human gene therapy. Semin Interv Cardiol 1996:1:84-88.
16. Escriou V, Ciolina C, Lacroix F. Byk G, Scherman D, Wils P: Cationic lipid-mediatcd gene transfer: Effect of serum on cellular uptake and intracellular fate of lipopolyamine/DNA complexes. Biochim Biophys Acta Biomembr 1998; 1368:276-288.
17. Zhou H, Zeng G, Zhou A, Tang J, Huang Q, Chen G, Peng T, Hu B: Adenovirus mediated gene transfer of vascular smooth muscle cells and endothelial cells in vitro. Chin Med J (Engl) 1995; 108:493-496.
18. Felgner PI, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M: Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7417.
19. Teifel M, Heine LT, Milbredt S, Friedl P: Optimization of transfection of human endothelial cells. Endothelium 1997;5:21-35.
20. Pickering JG, Jekanowski J, Weir L, Takeshita S, Losordo DW, Isner JM: Liposome-mediated gene transfer into human vascular smooth muscle cells. Circulation 1994;89: 13-21.
21. Gao X, Huang L: Cationic liposome-mediated gene-transfer. Gene Ther 1995:2:710-722.
22. Lewis JG, Lin KY, Kothavale A, Flanagan WM, Matteucci MD, DePrince RB, Mook RA Jr, Hendren RW, Wagner RW: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA 1996;93:3176-3181.
23. Xu M, Chen QR, Kumar D, Stass SA, Mixson AJ: In vivo gene therapy with a cationic polymer markedly enhances the antitumor activity of antiangiogenic genes. Mol Gen Metabol 1998:64:193-197.
24. Axel DI, Riessen R, Athanasiadis A, Runge H, Köveker G, Karsch KR: Growth factor expression of human arterial smooth muscle cells and endothelial cells in a transfilter coculture system. J Mol Cell Cardiol 1997;29:2967-2978.
25. Axel DI, Brehm BR, Wolburg-Buchholz K, Betz EL, Köveker G, Karseh KR: Induction of cell-rich and lipid-rich plaques in a transfilter coculture system with human vascular cells. J Vasc Res 1996;33:327-339.
26. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. J Immunol Meth 1986;89:271-277.
27. Lin AH, Gorman RR: Regulation of prostaglandin H synthase mRNA levels and prostaglandin biosynthesis by platelet-derived growth factor. J Biol Chem 1989;264:17379-17383.
28. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
29. Collins T, Ginsburg D, Boss JM, Orkin SH, Pober JS: Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis. Nature 1985:316:748-750.
30. Dernyek R, Jarret JA, Chen EY, Eaton DH, Bell J, Assoian RK, Roberts AB, Sporn MB, Goeddel DV: Human transforming growth factor-β cDNA sequence and expression in tumor cell lines. Nature 1985;316:701-705.
31. Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods useful in circulation research. Circ Res 1980;47:1-9.
32. Askari F, McDonnell WM: Molecular medicine. Antisense-oligonucleotide therapy. N Engl J Med 1996:334:316-318.
33. Gewirtz AM, Stein CA, Glazer PM: Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc Natl Acad Sci USA 1996;93:3161-3163.
34. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992;41:1023-1033.
35. Wagner RW: The state of the art in antisense research. Nat Med 1995;1:1116-1118.
36. Beltinger C. Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 1995:95:1814-1823.
37. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 1994:372:333-335.
38. Albrecht T, Sehwah R, Peschel C, Engels HJ, Fischer T, Huher C, Aulitzky WE: Cationic lipid mediated transfer of c-alb and ber antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modulation of gene expression. Ann Hematol 1996:72:73-79.
39. Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B: Intracellular distribution of microinjected oligonucleotides. Proc Natl Acad Sci USA 1991:88:2702-2706.
40. Sharma HW, Narayanan R: The therapeutic potential ol antisense oligonucleotides. Bioessays 1995;17:1055-1063.
41. Burgess TL, Fisher E, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SSF, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995;92:4051-4055.
42. Thierry AR, Dritsehilo A: Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligonucleotides for antisense activity. Nucleic Acids Res 1992;20: 5691-5698.
43. Keogh MC, Chen D, Lupu F, Shaper N, Schmitt JF, Kakkar W, Lemoine NR: High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid-DNA complex. Gene Ther 1997;4:162-171.
44. Jun CD, Choi BM, Kim SU, Lec SY, Kim HM, Chung HT: Down-regulation of transforming growth factor-beta gene expression by antisense oligodeoxynucleotides increases recombinant interferon-gamma-induced nitric oxide synthesis in murine peritoneal macrophages. Immunology 1995;85:114-119.
45. Liu M, Liu J, Buch S, Tanswell AK, Post M: Antisense oligonucleotides for PDGF-B and its receptor inhibit mechanical strain-induced fetal lung cell growth. Am J Physiol 1995;269: L178-L184.
46. Chavany C, Connell Y, Neckers L: Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 1995;48:738-746.
47. 1 inhibits proteoglycan synthesis in arterial wall. J Vasc Res 1994;31:322-329.
48. Kaneda Y, Morishita R, Dzau VJ: Prevention of restenosis by gene therapy. Ann NY Acad Sci 1997;811:299-308.
49. Gibbons GH, Dzau VJ: Molecular therapies for vascular diseases. Science 1996;272:689-693.
50. Nabel EG, Plautz G, Nabel GJ: Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990;249:1285-1288.
51. Rosenberg RD: Vascular smooth muscle cell proliferation: Basic investigations and new therapeutic approaches. Thromb Haemost 1993;70:10-16.
52. Tanner FC, Carr DP, Nabel GJ, Nabel EG: Transfection of human endothelial cells. Cardiovasc Res 1997;35:522-528.
53. Brysch W, Schlingensiepen KH: Design and application of antisense oligonucleotide in cell culture, in vivo, and as therapeutic agents. Cell Mol Neurobiol 1994;14:557-568.
54. Moulds C, Lewis JC, Froehler BC, Grant D, Huang T, Milligan JF, Matteucci MD, Wagner RW: Site and mechanism of antisense inhibition by C-5 propyne oligonucleotidcs. Biochemistry 1995:34:5044-5053.
55. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T: Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 1993;88:2838-2848.
56. Molnar-Kimber KE, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M, Elshami A, Gelland K, Wilson JM, Kaiser LR, Albelda SM: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998;9:2121-2133.
57. Mazur W, Ali NM, Grinstead WC, Schulz DG, Raizner AE, French BA: Lipofectin-mediated versus adenovirus-mediated gene transfer in vitro and in vivo; Comparison of canine and porcine model systems. Coron Artery Dis 1994;5:779-786.